Actinium-225 possesses the resounding potential to treat cancers more effectively. Initial results show that the theranostic radioisotope completely eliminates cancer cells, rather than just inhibiting tumour growth. The risk of recurrence also appears to decrease. To date, extensive research and numerous studies are underway which aim to tackle both high prevalence cancers including prostate, lung, colon, breast, pancreatic, blood (leukemia and other rare forms) and kidney cancers, but also rarer forms of cancer like glioblastoma, the deadliest form of a very invasive brain cancer.
Quality remanufactured Certified Centrifuges at Great prices! Fully warranted and backed by a company you can trust! Call or click for a free quote today! www.Centrifugestore.com 800-457-7576
IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA is also a leading player in the fields of industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 1,600 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.
IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).
About SCK CEN
SCK CEN is one of Belgium’s largest research centres. It has more than 850 employees who devote themselves every day to developing peaceful applications of nuclear energy. The research activities of SCK CEN relate to three main themes: the safety of nuclear facilities, the development of nuclear medicine and protecting the population and the environment against ionising radiation. SCK CEN is recognised worldwide and shares its knowledge through numerous publications and training courses in order to keep up this exceptional pool of talent.Back to HCB News